Frequency and Risk Factors for Secondary Malignancies in Patients With Mycosis Fungoides

Cengiz, Fatma Pelin; Emiroğlu, Nazan; Onsun, Nahide

doi:10.4274/tjh.2017.0234

Cited by 3 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on prior work by this group and others, it is apparent that patients with MF are at increased risk of second haematologic and solid malignancies 1‐12 . The specific malignancies found to have significantly elevated risk are NHL, HL, lung cancer, bladder cancer and melanoma 13 .…”

Section: Discussionmentioning

confidence: 98%

“…21,22 The biggest weakness of this analysis is that data on smoking (and other behavioural traits) are not recorded in SEER, nor was smoking status noted in any prior papers on the subject of second malignancies in MF. [1][2][3][4][5][6][7][8][9][10][11][12] One piece of evidence that supports a role for smoking in second malignancy patients is that lung cancer patients were seen to frequently die from other additional smoking-associated malignanciesstomach cancer, oesophageal cancer and bladder cancer. Although the sample size is small and statistical significance cannot be appropriately assessed, it is noteworthy that all of these cancers are Table 4 Recommended review of systems, history questions, physical examination and counselling for patients with mycosis fungoides, in addition to ensuring all age-and sex-appropriate cancer screenings are up-to-date strongly associated with smoking.…”

Section: Discussionmentioning

confidence: 99%

“…The phenomenon of diagnosis of second malignancies in patients with mycosis fungoides (MF) has gained increased recognition in the dermatology literature 1‐12 . A recent meta‐analysis performed by our group identified non‐Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), lung cancer, bladder cancer and melanoma as the second malignancies most likely to occur in a patient with MF 13 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Screening for second malignancies in mycosis fungoides: non‐Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma

Goyal

O’Leary

Goyal

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Patients with mycosis fungoides (MF) are at increased risk of developing non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), lung cancer, bladder cancer and melanoma. The characteristics of patients developing these malignancies have not been specifically delineated. In addition, there are no established guidelines for screening MF patients for second malignancies. Materials/MethodsWe identified 742 patients with MF who developed second malignancies in the Surveillance Epidemiology and End Result-18 database. ResultsThe majority of second malignancy patients were white and male, mean age 55-67 years at diagnosis of MF, and mean age 61-72 years at diagnosis of second malignancy. The majority of patients diagnosed with second malignancies had early stage MF. MF patients with NHL, lung cancer, and bladder cancer tended to be diagnosed at earlier stages of the second malignancy than patients without MF and demonstrated better 5-year overall survival. There was no improvement in stage at diagnosis or survival for MF patients who were diagnosed with melanoma compared to patients without MF.Conclusions Improvements in survival in MF/NHL, MF/lung cancer and MF/bladder cancer patients may reflect differences in disease biology secondary to having MF or the importance of increased contact with the healthcare system. MF/melanoma data suggest that patients require regular pigmented-lesion-focused skin examinations. Tools for screening include regular lymph node examinations, pigmented-lesion-focused examinations and detailed review of systems questions. Smoking cessation counseling is key intervention in this population, as is ensuring that all age-and sexspecific cancer screenings are up-to-date (e.g. lung cancer screening, mammography, and colonoscopy). The utility of regular imaging for second malignancy screening and lab testing such as routine urinalysis requires additional study and expert consensus.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Screening for second malignancies in mycosis fungoides: non‐Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma

Goyal

O’Leary

Goyal

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Previous epidemiological data revealed that the factors associated with the increased risk of secondary solid tumours are: stage IV of the disease, the presence of lymphomatoid papulosis, and duration of the disease (more than 10 years). Furthermore, for the vast majority of the patients, secondary malignancies occurred within the first year of the diagnosis of MF (60%) [ 8 ]. According to Cengiz et al ., older age, higher stage of MF, and the presence of lymphomatoid papulosis are factors associated with increased risk of the coexistence of two other malignancies besides MF [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, for the vast majority of the patients, secondary malignancies occurred within the first year of the diagnosis of MF (60%) [ 8 ]. According to Cengiz et al ., older age, higher stage of MF, and the presence of lymphomatoid papulosis are factors associated with increased risk of the coexistence of two other malignancies besides MF [ 8 ]. In our study, only 2 patients with MF were diagnosed with co-existing kidney cancer and lymphomatoid papulosis, and B-cell lymphoma and teratoma malignum, respectively.…”

Section: Discussionmentioning

confidence: 99%

The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome

Błażewicz¹,

Olszewska²,

Stawczyk-Macieja³

et al. 2021

pdia

View full text Add to dashboard Cite

Introduction: Cutaneous T-cell lymphomas (CTCLs) are a diverse group of non-Hodgkin's lymphomas with malignant T lymphocytes infiltrating the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) belong to the group of CTCLs, among others. In previous studies it was suggested that primary cancers more often occur in patients with cutaneous lymphoma. Aim: To analyse the incidence of other malignancies in CTCL patients. Material and methods: The evaluation of the coexistence of primary malignant neoplasms in CTCL patients was conducted by analysis of the patients' database, with diagnosis of mycosis fungoides and Sézary syndrome, treated in the Dermatological Department of the Medical University of Gdansk between 2010 and 2018. Results: Among CTCL patients, 177 were diagnosed with MF/SS (stage MFIA 37.61%, MFIB 30.77%, MFIIA 0.85%, MFIIB 11.11%, MFIII 8.55% MFIV 4.27%; SS 6.84%). The group was characterized by a male-to-female ratio of 1.21 : 1. 16.94% of MF/SS patients had one co-existing cancer, while 1.13% of patients had 2 co-existing cancers; the most common were basal cell carcinoma, lymphomatoid papulosis, lung cancer, and B-cell lymphoma. The obtained data highlight that MF/SS is associated with increased risk of cancer. Conclusions: Our study suggests that special attention should be paid to careful examination of CTCL patientswhat force to perform solid clinical examination, the X-ray chest examination, abdomen USG, mammography, and others, even in early stages of MF/SS. Clinicians should be aware of the coexistence of other neoplasms such as lung, skin, and breast cancer.

show abstract

Evaluation of secondary malignancies in a large series of mycosis fungoides

Atci,

Yerlioğlu Ak,

Baykal

2024

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

Frequency and Risk Factors for Secondary Malignancies in Patients With Mycosis Fungoides

Cited by 3 publications

References 4 publications

Screening for second malignancies in mycosis fungoides: non‐Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma

Screening for second malignancies in mycosis fungoides: non‐Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma

The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome

Evaluation of secondary malignancies in a large series of mycosis fungoides

Contact Info

Product

Resources

About